Results 201 to 210 of about 5,441,121 (300)

Marketing features of derived intoxicating cannabinoid product brands on Instagram: A content analysis

Addiction, EarlyView.
Abstract Background and aims Use of derived intoxicating cannabinoid products (DICPs) has grown in the United States (US), as have associated poisonings, emergency department visits and psychotic episodes. Brand marketing on social media, a largely underregulated marketing channel, may be contributing to this growth.
Kathryn La Capria, Siyan Meng, Alisa A. Padon, Kayla K. Tillett, Scott I. Donaldson, Jon‐Patrick Allem, Matthew E. Rossheim, Cassidy LoParco, Carla J. Berg, Kristina M. Jackson, Julia Chen‐Sankey   +10 more
wiley   +1 more source

Medical Cannabis and Opioid Receipt Among Adults With Chronic Pain. [PDF]

JAMA Intern Med
Slawek DE, Zhang C, Dahmer S, Sohler N, Zolotov Y, Starrels JL, Deng Y, Calderon DiFrancesca G, Levin FR, Ross J, Minami H, Cunningham CO, Arnsten JH.   +12 more
europepmc   +1 more source

Problems in comparing tobacco regulatory models and excise when only two countries are considered

Addiction, EarlyView.
Simon Chapman, Sam Egger, Becky Freeman
wiley   +1 more source

Towards the implementation of cannabis‐focused apps in early intervention services for psychosis: A qualitative investigation of patient and clinician perspectives

Addiction, EarlyView.
Abstract Background and aims Cannabis use is highly prevalent among young adults with first‐episode psychosis (FEP) and is associated with poorer clinical and functional outcomes. Mobile health interventions may help address structural barriers to delivering cannabis‐focused psychosocial interventions within early intervention services (EIS), yet ...
Selim Abou‐Rahal, Alexis Doucet, Pamela Lachance‐Touchette, Amal Abdel‐Baki, Stephanie Coronado‐Montoya, José Côté, Ovidiu Tatar, Philip G. Tibbo, Didier Jutras‐Aswad   +8 more
wiley   +1 more source

Joint associations of recovery capital and polygenic risk with electronic health record observed remission and relapse in substance use disorder: Longitudinal evidence from the All of Us research program

Addiction, EarlyView.
Abstract Background and aims Recovery capital and genetic liability may be related to substance use disorder (SUD) remission through psychosocial and biologic pathways, but their joint association with remission course remains poorly understood. This question is clinically important because people entering remission differ in recovery resources and ...
Janaka V. Kosgolla, Douglas C. Smith
wiley   +1 more source

Clinical Experience and Student Support for Medical Cannabis Use: A Secondary Analysis. [PDF]

Cannabis
Tong AW, DuBoux CJ, Seuferer RH, Clobes TA, Siu FW, Magana B, Gold JM, Bensing-Ruiz J.   +7 more
europepmc   +1 more source

Clinical applications of wearable devices for individuals with at‐risk substance use and substance use disorders: A systematic review

The American Journal on Addictions, EarlyView.
Abstract Background and Objectives Managing substance use disorders (SUDs) is limited by the lack of longitudinal clinical data during active use and recovery. Wearable devices may help address this gap by capturing physiological and behavioral data in real‐world settings.
Alexandra Sas, Matthew E. Sloan, Yaoyi Xing, Ethan Kim, Dhvani Mehta, Anna Mouzenian, Lena C. Quilty, Jeffrey D. Wardell, Shannon Lange, Daniel Felsky, Victor M. Tang   +10 more
wiley   +1 more source

Medical cannabis utilization in children - a study based on a nationwide cohort. [PDF]

Front Pharmacol
Treves N, Yakirevich-Amir N, Allegaert K, van den Anker JN, Kohn E, Berlin M, Hazan A, Davidson E, Berkovitch M, Bonne O, Stolar OE, Matok I.   +11 more
europepmc   +1 more source

Proof‐of‐concept trial of PP‐01 for mitigating cannabis withdrawal syndrome in participants with cannabis use disorder

The American Journal on Addictions, EarlyView.
Abstract Background and Objectives Cannabis withdrawal symptoms can be severe and protracted, significantly impeding the ability to abstain from cannabis use, resulting in failed quit attempts and relapse. This clinical trial evaluated safety and efficacy of PP‐01, a novel dual‑mechanism of action, investigational agent, for mitigating cannabis ...
Ashley F. Slagle, Jay Constantine, Harvey Kushner, Shelli Graham, Ginger Constantine   +4 more
wiley   +1 more source

Unmet Healthcare Needs as a Mechanism of Rural-Urban Medical Cannabis Use Disparities Among Sexual Minority Young Adults. [PDF]

J Rural Health
Anderson CB, Romm KF, Vogel EA.
europepmc   +1 more source